ZA200306432B - Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors. - Google Patents

Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors. Download PDF

Info

Publication number: ZA200306432B
Authority: ZA; South Africa
Prior art keywords: optionally; substituted; compound; formula; phenyl
Prior art date: 2001-04-09

Application number

ZA200306432A

Other languages

English (en)

Inventor

Rainer Albert

Christian Bruns

Francois Nuninger

Markus Streiff

Gebhard Thoma

Hans-Guenter Zerwes

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-09

Filing date

2003-08-19

Publication date

2004-06-04

2003-08-19 Application filed by Novartis Ag filed Critical Novartis Ag

2004-06-04 Publication of ZA200306432B publication Critical patent/ZA200306432B/en

Links

102000009410 Chemokine receptor Human genes 0.000 title claims description 5
108050000299 Chemokine receptor Proteins 0.000 title claims description 5
239000003112 inhibitor Substances 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 86
238000000034 method Methods 0.000 claims description 42
239000000203 mixture Substances 0.000 claims description 32
125000000217 alkyl group Chemical group 0.000 claims description 22
125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
150000003839 salts Chemical group 0.000 claims description 21
125000001072 heteroaryl group Chemical class 0.000 claims description 18
125000003342 alkenyl group Chemical group 0.000 claims description 16
-1 heteroaryl N-oxide Chemical class 0.000 claims description 14
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
125000000753 cycloalkyl group Chemical group 0.000 claims description 12
125000000304 alkynyl group Chemical group 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
102000007399 Nuclear hormone receptor Human genes 0.000 claims description 9
108020005497 Nuclear hormone receptor Proteins 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 8
125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
239000003446 ligand Substances 0.000 claims description 7
125000001424 substituent group Chemical group 0.000 claims description 7
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
125000001188 haloalkyl group Chemical group 0.000 claims description 6
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
229910052760 oxygen Inorganic materials 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
125000006574 non-aromatic ring group Chemical group 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
238000006268 reductive amination reaction Methods 0.000 claims description 5
125000005073 adamantyl group Chemical class C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 4
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
125000003983 fluorenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 4
230000001404 mediated effect Effects 0.000 claims description 4
125000001624 naphthyl group Chemical class 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
125000005842 heteroatom Chemical group 0.000 claims description 3
230000003993 interaction Effects 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
230000002862 amidating effect Effects 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
239000002904 solvent Substances 0.000 description 17
239000000243 solution Substances 0.000 description 15
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
229910052938 sodium sulfate Inorganic materials 0.000 description 14
235000011152 sodium sulphate Nutrition 0.000 description 14
239000007787 solid Substances 0.000 description 13
239000007858 starting material Substances 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
238000004587 chromatography analysis Methods 0.000 description 11
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
239000012267 brine Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
239000005557 antagonist Substances 0.000 description 6
230000002519 immonomodulatory effect Effects 0.000 description 6
230000002757 inflammatory effect Effects 0.000 description 6
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 5
239000000556 agonist Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
229940035422 diphenylamine Drugs 0.000 description 5
230000001506 immunosuppresive effect Effects 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
ZOERGUNJWYRHNM-UHFFFAOYSA-N 1-(4-methylpiperidin-4-yl)-n,n-diphenylpiperidin-4-amine Chemical compound C1CC(N(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C1(C)CCNCC1 ZOERGUNJWYRHNM-UHFFFAOYSA-N 0.000 description 4
GZEYDQSXPQERSX-UHFFFAOYSA-N 1-[1-(2,6-dimethylbenzoyl)-4-methylpiperidin-4-yl]piperidin-4-one Chemical compound CC1=CC=CC(C)=C1C(=O)N1CCC(C)(N2CCC(=O)CC2)CC1 GZEYDQSXPQERSX-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 4
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
238000010511 deprotection reaction Methods 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
HTIWISWAPVQGMI-UHFFFAOYSA-N tert-butyl 4-anilinopiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=CC=C1 HTIWISWAPVQGMI-UHFFFAOYSA-N 0.000 description 4
238000011282 treatment Methods 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
HCBHQDKBSKYGCK-UHFFFAOYSA-N 2,6-dimethylbenzoic acid Chemical compound CC1=CC=CC(C)=C1C(O)=O HCBHQDKBSKYGCK-UHFFFAOYSA-N 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 3
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
229960003444 immunosuppressant agent Drugs 0.000 description 3
230000001861 immunosuppressant effect Effects 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 3
HVHADFORFKGQAD-UHFFFAOYSA-N n,n-diphenylpiperidin-4-amine Chemical compound C1CNCCC1N(C=1C=CC=CC=1)C1=CC=CC=C1 HVHADFORFKGQAD-UHFFFAOYSA-N 0.000 description 3
ZYOULGUBXSMPCJ-UHFFFAOYSA-N n-(4-bromophenyl)-n-phenylpiperidin-4-amine Chemical compound C1=CC(Br)=CC=C1N(C=1C=CC=CC=1)C1CCNCC1 ZYOULGUBXSMPCJ-UHFFFAOYSA-N 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
KOGVROJCZJTRSY-UHFFFAOYSA-N (2,6-dimethylphenyl)-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-4-methylpiperidin-1-yl]methanone Chemical compound CC1=CC=CC(C)=C1C(=O)N1CCC(C)(N2CCC3(CC2)OCCO3)CC1 KOGVROJCZJTRSY-UHFFFAOYSA-N 0.000 description 2
XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 2
WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 2
PWQVPTZORSSXPH-UHFFFAOYSA-N 8-(1-benzyl-4-methylpiperidin-4-yl)-1,4-dioxa-8-azaspiro[4.5]decane Chemical compound C1CC(C)(N2CCC3(CC2)OCCO3)CCN1CC1=CC=CC=C1 PWQVPTZORSSXPH-UHFFFAOYSA-N 0.000 description 2
HQZLIFQOVGDWOX-UHFFFAOYSA-N 8-(4-methylpiperidin-4-yl)-1,4-dioxa-8-azaspiro[4.5]decane Chemical compound C1CC2(OCCO2)CCN1C1(C)CCNCC1 HQZLIFQOVGDWOX-UHFFFAOYSA-N 0.000 description 2
229940122739 Calcineurin inhibitor Drugs 0.000 description 2
101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 2
102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 2
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102100025390 Integrin beta-2 Human genes 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
230000002924 anti-infective effect Effects 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002825 functional assay Methods 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
VSNCRJKUYAVXCC-UHFFFAOYSA-N n-(4-bromophenyl)-n-phenyl-1-piperidin-4-ylpiperidin-4-amine Chemical compound C1=CC(Br)=CC=C1N(C=1C=CC=CC=1)C1CCN(C2CCNCC2)CC1 VSNCRJKUYAVXCC-UHFFFAOYSA-N 0.000 description 2
LKRMTUUCKBQGFO-UHFFFAOYSA-N n-phenylpiperidin-4-amine Chemical compound C1CNCCC1NC1=CC=CC=C1 LKRMTUUCKBQGFO-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000002265 prevention Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
YQAPDWFBEYBTKX-UHFFFAOYSA-N tert-butyl 4-(4-anilinopiperidin-1-yl)-4-methylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C)N1CCC(NC=2C=CC=CC=2)CC1 YQAPDWFBEYBTKX-UHFFFAOYSA-N 0.000 description 2
ZDCRNXMZSKCKRF-UHFFFAOYSA-N tert-butyl 4-(4-bromoanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=C(Br)C=C1 ZDCRNXMZSKCKRF-UHFFFAOYSA-N 0.000 description 2
WXPBGQXYRWMVGB-UHFFFAOYSA-N tert-butyl 4-(n-(4-bromophenyl)anilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC(Br)=CC=1)C1=CC=CC=C1 WXPBGQXYRWMVGB-UHFFFAOYSA-N 0.000 description 2
YLLQWQAWIYVBOZ-UHFFFAOYSA-N tert-butyl 4-(n-phenylanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C=1C=CC=CC=1)C1=CC=CC=C1 YLLQWQAWIYVBOZ-UHFFFAOYSA-N 0.000 description 2
MDIHVHPFRRMPIT-UHFFFAOYSA-N tert-butyl 4-[4-(n-(4-bromophenyl)anilino)piperidin-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1CCC(N(C=2C=CC=CC=2)C=2C=CC(Br)=CC=2)CC1 MDIHVHPFRRMPIT-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KWPAQVVTTPTSTI-UHFFFAOYSA-N (2,6-dimethylphenyl)-[4-[4-(n-phenylanilino)piperidin-1-yl]piperidin-1-yl]methanone Chemical compound CC1=CC=CC(C)=C1C(=O)N1CCC(N2CCC(CC2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 KWPAQVVTTPTSTI-UHFFFAOYSA-N 0.000 description 1
CXINWYOAJHTJKP-UHFFFAOYSA-N (2,6-dimethylphenyl)-[4-[4-(n-pyridin-3-ylanilino)piperidin-1-yl]piperidin-1-yl]methanone Chemical compound CC1=CC=CC(C)=C1C(=O)N1CCC(N2CCC(CC2)N(C=2C=CC=CC=2)C=2C=NC=CC=2)CC1 CXINWYOAJHTJKP-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
SWJPEBQEEAHIGZ-UHFFFAOYSA-N 1,4-dibromobenzene Chemical compound BrC1=CC=C(Br)C=C1 SWJPEBQEEAHIGZ-UHFFFAOYSA-N 0.000 description 1
KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
YYWRFOKOJAPOJM-UHFFFAOYSA-N 1-(4-methylpiperidin-4-yl)-n-[(2-methyl-1,3-thiazol-4-yl)methyl]-n-phenylpiperidin-4-amine Chemical compound S1C(C)=NC(CN(C2CCN(CC2)C2(C)CCNCC2)C=2C=CC=CC=2)=C1 YYWRFOKOJAPOJM-UHFFFAOYSA-N 0.000 description 1
DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
PKJBWOWQJHHAHG-UHFFFAOYSA-N 1-bromo-4-phenylbenzene Chemical group C1=CC(Br)=CC=C1C1=CC=CC=C1 PKJBWOWQJHHAHG-UHFFFAOYSA-N 0.000 description 1
PVJZBZSCGJAWNG-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonyl chloride Chemical compound CC1=CC(C)=C(S(Cl)(=O)=O)C(C)=C1 PVJZBZSCGJAWNG-UHFFFAOYSA-N 0.000 description 1
QOJQBWSZHCKOLL-UHFFFAOYSA-N 2,6-dimethylbenzaldehyde Chemical compound CC1=CC=CC(C)=C1C=O QOJQBWSZHCKOLL-UHFFFAOYSA-N 0.000 description 1
NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
SBJRXHBKPCHGQY-UHFFFAOYSA-N 4,6-dimethylpyrimidine-5-carboxylic acid Chemical compound CC1=NC=NC(C)=C1C(O)=O SBJRXHBKPCHGQY-UHFFFAOYSA-N 0.000 description 1
ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
101000980996 Arabidopsis thaliana Phosphatidate cytidylyltransferase 3 Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
JPECXUJKKQDTPF-UHFFFAOYSA-N C1CC(N(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C1(C)CCN(C(O)=O)CC1 Chemical compound C1CC(N(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C1(C)CCN(C(O)=O)CC1 JPECXUJKKQDTPF-UHFFFAOYSA-N 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
108010021064 CTLA-4 Antigen Proteins 0.000 description 1
102000008203 CTLA-4 Antigen Human genes 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
208000021709 Delayed Graft Function Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
244000287680 Garcinia dulcis Species 0.000 description 1
102400000185 HCC-1(9-74) Human genes 0.000 description 1
101800003455 HCC-1(9-74) Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
101000623713 Homo sapiens Motile sperm domain-containing protein 3 Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
102100023091 Motile sperm domain-containing protein 3 Human genes 0.000 description 1
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
DMBHHRLKUKUOEG-UHFFFAOYSA-N N-phenyl aniline Natural products C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 1
HIEKJRVYXXINKH-ADVKXBNGSA-N N1([C@H]2CC[C@H](C[C@H]2OC)/C=C(\C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]3(O)O[C@@H]([C@H](C[C@H]3C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]2C)=O)CC)C=NN=N1 Chemical compound N1([C@H]2CC[C@H](C[C@H]2OC)/C=C(\C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]3(O)O[C@@H]([C@H](C[C@H]3C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]2C)=O)CC)C=NN=N1 HIEKJRVYXXINKH-ADVKXBNGSA-N 0.000 description 1
208000013901 Nephropathies and tubular disease Diseases 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010038460 Renal haemorrhage Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010062106 Respiratory tract infection viral Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
206010044541 Traumatic shock Diseases 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
BHTPRZZPTGOHLP-UHFFFAOYSA-N [4-[4-(n-(4-bromophenyl)anilino)piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,6-dimethylphenyl)methanone Chemical compound CC1=CC=CC(C)=C1C(=O)N1CCC(C)(N2CCC(CC2)N(C=2C=CC=CC=2)C=2C=CC(Br)=CC=2)CC1 BHTPRZZPTGOHLP-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
238000011316 allogeneic transplantation Methods 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940124522 antiretrovirals Drugs 0.000 description 1
239000003903 antiretrovirus agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 1
239000002559 chemokine receptor antagonist Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
229940126523 co-drug Drugs 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
ZOGHDTBRWUEJDP-UHFFFAOYSA-N diethylalumanylium;cyanide Chemical compound N#[C-].CC[Al+]CC ZOGHDTBRWUEJDP-UHFFFAOYSA-N 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
229960000556 fingolimod Drugs 0.000 description 1
KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
230000004907 flux Effects 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
231100000753 hepatic injury Toxicity 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
201000010659 intrinsic asthma Diseases 0.000 description 1
208000001875 irritant dermatitis Diseases 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
239000000463 material Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229950000844 mizoribine Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
229960004866 mycophenolate mofetil Drugs 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
QNXIWEZMHZNMCV-UHFFFAOYSA-N n,n-diphenyl-1-piperidin-4-ylpiperidin-4-amine Chemical compound C1CNCCC1N1CCC(N(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 QNXIWEZMHZNMCV-UHFFFAOYSA-N 0.000 description 1
USLFKUFTSCJSHZ-UHFFFAOYSA-N n-phenyl-n-piperidin-4-ylpyridin-3-amine Chemical compound C1CNCCC1N(C=1C=NC=CC=1)C1=CC=CC=C1 USLFKUFTSCJSHZ-UHFFFAOYSA-N 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000004576 sand Substances 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
125000002345 steroid group Chemical group 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
231100000617 superantigen Toxicity 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229960000235 temsirolimus Drugs 0.000 description 1
SGWSPSSRJWXVTE-UHFFFAOYSA-N tert-butyl 4-(pyridin-3-ylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=CN=C1 SGWSPSSRJWXVTE-UHFFFAOYSA-N 0.000 description 1
CCOICZDOKLQTOX-UHFFFAOYSA-N tert-butyl 4-[4-(n-phenylanilino)piperidin-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1CCC(N(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 CCOICZDOKLQTOX-UHFFFAOYSA-N 0.000 description 1
SDDFJFPUKXLWMA-UHFFFAOYSA-N tert-butyl 4-[4-(trifluoromethyl)anilino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=C(C(F)(F)F)C=C1 SDDFJFPUKXLWMA-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
229950009819 zotarolimus Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Oncology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)

ZA200306432A 2001-04-09 2003-08-19 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors. ZA200306432B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0108876.4A GB0108876D0 (en)	2001-04-09	2001-04-09	Organic Compounds

Publications (1)

Publication Number	Publication Date
ZA200306432B true ZA200306432B (en)	2004-06-04

Family

ID=9912541

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200306432A ZA200306432B (en)	2001-04-09	2003-08-19	Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors.

Country Status (27)

Country	Link
US (1)	US20040142920A1 (es)
EP (1)	EP1379504B1 (es)
JP (1)	JP4366079B2 (es)
KR (1)	KR100616039B1 (es)
CN (1)	CN100469767C (es)
AR (1)	AR035815A1 (es)
AT (1)	ATE446950T1 (es)
AU (1)	AU2002302511B2 (es)
BR (1)	BR0208741A (es)
CA (1)	CA2439241C (es)
CZ (1)	CZ20032723A3 (es)
DE (1)	DE60234167D1 (es)
EC (1)	ECSP034765A (es)
ES (1)	ES2335393T3 (es)
GB (1)	GB0108876D0 (es)
HU (1)	HUP0303724A3 (es)
IL (1)	IL157428A0 (es)
MX (1)	MXPA03009220A (es)
NO (1)	NO20034324D0 (es)
NZ (1)	NZ528712A (es)
PE (1)	PE20021004A1 (es)
PL (1)	PL363011A1 (es)
PT (1)	PT1379504E (es)
RU (1)	RU2296751C2 (es)
SK (1)	SK12422003A3 (es)
WO (1)	WO2002081449A1 (es)
ZA (1)	ZA200306432B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1545509A (zh)	2001-07-02	2004-11-10		用作趋化因子受体活性调节剂的哌啶衍生物
GB0120461D0 (en)	2001-08-22	2001-10-17	Astrazeneca Ab	Novel compounds
AR036366A1 (es)	2001-08-29	2004-09-01	Schering Corp	Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en)	2001-09-18	2001-11-07	Astrazeneca Ab	Chemical compounds
SE0200844D0 (sv)	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0200843D0 (sv)	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0202838D0 (sv) *	2002-09-24	2002-09-24	Astrazeneca Ab	Chemical compounds
JP2006513151A (ja) *	2002-10-04	2006-04-20	ユセベソシエテアノニム	４−アミノピペリジン誘導体、その製造方法及び医薬品としての使用
GB0223223D0 (en) *	2002-10-07	2002-11-13	Novartis Ag	Organic compounds
DE60324014D1 (de) *	2002-12-13	2008-11-20	Smithkline Beecham Corp	Heterocyclische verbindungen alsccr5-antagonisten
SE0300957D0 (sv)	2003-04-01	2003-04-01	Astrazeneca Ab	Chemical compounds
JPWO2004092136A1 (ja) *	2003-04-18	2006-07-06	小野薬品工業株式会社	含窒素複素環化合物およびその用途
FR2854158B1 (fr) *	2003-04-25	2006-11-17	Sanofi Synthelabo	Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
WO2004113323A1 (en) *	2003-06-13	2004-12-29	Schering Aktiengesellschaft	Quinolyl amide derivatives as ccr-5 antagonists
US7652142B2 (en) *	2003-11-03	2010-01-26	Schering Corporation	Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
US7498346B2 (en) *	2003-12-11	2009-03-03	Genzyme Corporation	Chemokine receptor binding compounds
US7381738B2 (en)	2004-02-19	2008-06-03	Bristol-Myers Squibb Company	Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en)	2004-02-19	2009-01-20	Bristol-Myers Squibb Company	Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en)	2004-02-19	2007-06-12	Bristol-Myers Squibb Company	Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7288563B2 (en)	2004-02-19	2007-10-30	Bristol-Myers Squibb Company	Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
EP1844037A1 (en) *	2005-01-20	2007-10-17	Pfizer Limited	Chemical compounds
KR20080037655A (ko)	2005-07-21	2008-04-30	아스트라제네카 아베	신규 피페리딘 유도체
WO2008030853A2 (en) *	2006-09-06	2008-03-13	Incyte Corporation	Combination therapy for human immunodeficiency virus infection
WO2008070758A1 (en) *	2006-12-06	2008-06-12	Genzyme Corporation	Chemokine receptor binding compounds
CA2756870A1 (en)	2009-03-31	2010-10-07	Arqule, Inc.	Substituted indolo-pyridinone compounds
EP2683643B1 (en)	2011-03-09	2019-05-08	Richard G. Pestell	Prostate cancer cell lines, gene signatures and uses thereof
WO2013173312A1 (en)	2012-05-14	2013-11-21	Pestell Richard G	Using modulators of ccr5 for treating cancer
EP3083610A1 (de)	2013-12-19	2016-10-26	Bayer Pharma Aktiengesellschaft	Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
JOP20200052A1 (ar)	2013-12-19	2017-06-16	Bayer Pharma AG	بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CN106029648A (zh)	2013-12-19	2016-10-12	拜耳制药股份公司	作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
AU2014364735A1 (en)	2013-12-19	2016-07-07	Bayer Pharma Aktiengesellschaft	Substituted piperidinyl-tetrahydroquinolines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2676054B1 (fr) *	1991-05-03	1993-09-03	Sanofi Elf	Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
TW531537B (en) *	1995-12-27	2003-05-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) *	1996-07-10	1999-09-14	Schering Corporation	Muscarinic antagonists for treating memory loss
NZ334543A (en) *	1996-09-10	2000-06-23	Thomae Gmbh Dr K	Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays
DE19637043A1 (de) *	1996-09-12	1998-03-19	Boehringer Mannheim Gmbh	Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
DE19643331A1 (de) *	1996-10-21	1998-04-23	Thomae Gmbh Dr K	1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6391865B1 (en) *	1999-05-04	2002-05-21	Schering Corporation	Piperazine derivatives useful as CCR5 antagonists
PT1175402E (pt) *	1999-05-04	2005-11-30	Schering Corp	Derivados da piperidina uteis como antagonistas ccr5
EP1192133B1 (en) *	1999-06-11	2006-11-02	Merck & Co., Inc.	N-cyclopentyl modulators of chemokine receptor activity
CA2413418A1 (en) *	2000-06-21	2001-12-27	Joseph B. Santella	Piperidine amides as modulators of chemokine receptor activity
EP1322628A2 (en) *	2000-09-14	2003-07-02	Schering Corporation	Substituted urea neuropeptide y y5 receptor antagonists
AR036366A1 (es) *	2001-08-29	2004-09-01	Schering Corp	Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0223223D0 (en) *	2002-10-07	2002-11-13	Novartis Ag	Organic compounds

2001
- 2001-04-09 GB GBGB0108876.4A patent/GB0108876D0/en not_active Ceased
2002
- 2002-04-05 AR ARP020101270A patent/AR035815A1/es not_active Application Discontinuation
- 2002-04-08 JP JP2002579437A patent/JP4366079B2/ja not_active Expired - Fee Related
- 2002-04-08 CZ CZ20032723A patent/CZ20032723A3/cs unknown
- 2002-04-08 ES ES02730122T patent/ES2335393T3/es not_active Expired - Lifetime
- 2002-04-08 CN CNB028079507A patent/CN100469767C/zh not_active Expired - Fee Related
- 2002-04-08 MX MXPA03009220A patent/MXPA03009220A/es active IP Right Grant
- 2002-04-08 KR KR1020037013161A patent/KR100616039B1/ko not_active Expired - Fee Related
- 2002-04-08 IL IL15742802A patent/IL157428A0/xx unknown
- 2002-04-08 PT PT02730122T patent/PT1379504E/pt unknown
- 2002-04-08 PL PL02363011A patent/PL363011A1/xx not_active Application Discontinuation
- 2002-04-08 AU AU2002302511A patent/AU2002302511B2/en not_active Ceased
- 2002-04-08 NZ NZ528712A patent/NZ528712A/en unknown
- 2002-04-08 BR BR0208741-3A patent/BR0208741A/pt not_active IP Right Cessation
- 2002-04-08 HU HU0303724A patent/HUP0303724A3/hu unknown
- 2002-04-08 AT AT02730122T patent/ATE446950T1/de not_active IP Right Cessation
- 2002-04-08 US US10/472,653 patent/US20040142920A1/en not_active Abandoned
- 2002-04-08 EP EP02730122A patent/EP1379504B1/en not_active Expired - Lifetime
- 2002-04-08 CA CA2439241A patent/CA2439241C/en not_active Expired - Fee Related
- 2002-04-08 DE DE60234167T patent/DE60234167D1/de not_active Expired - Lifetime
- 2002-04-08 RU RU2003130642/04A patent/RU2296751C2/ru not_active IP Right Cessation
- 2002-04-08 PE PE2002000282A patent/PE20021004A1/es not_active Application Discontinuation
- 2002-04-08 WO PCT/EP2002/003871 patent/WO2002081449A1/en not_active Ceased
- 2002-04-08 SK SK1242-2003A patent/SK12422003A3/sk not_active Application Discontinuation
2003
- 2003-08-19 ZA ZA200306432A patent/ZA200306432B/en unknown
- 2003-09-11 EC EC2003004765A patent/ECSP034765A/es unknown
- 2003-09-26 NO NO20034324A patent/NO20034324D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0303724A2 (hu)	2004-03-01
KR100616039B1 (ko)	2006-08-28
KR20030087066A (ko)	2003-11-12
CA2439241C (en)	2010-06-08
ECSP034765A (es)	2003-10-28
NZ528712A (en)	2005-07-29
NO20034324L (no)	2003-09-26
EP1379504B1 (en)	2009-10-28
JP4366079B2 (ja)	2009-11-18
EP1379504A1 (en)	2004-01-14
AU2002302511B2 (en)	2005-08-04
PT1379504E (pt)	2010-01-04
IL157428A0 (en)	2004-03-28
AR035815A1 (es)	2004-07-14
PE20021004A1 (es)	2003-01-03
MXPA03009220A (es)	2004-01-29
ATE446950T1 (de)	2009-11-15
PL363011A1 (en)	2004-11-15
WO2002081449A1 (en)	2002-10-17
BR0208741A (pt)	2004-06-22
RU2003130642A (ru)	2005-04-10
GB0108876D0 (en)	2001-05-30
CZ20032723A3 (cs)	2003-12-17
DE60234167D1 (de)	2009-12-10
CN1501915A (zh)	2004-06-02
CN100469767C (zh)	2009-03-18
US20040142920A1 (en)	2004-07-22
JP2004525174A (ja)	2004-08-19
ES2335393T3 (es)	2010-03-26
NO20034324D0 (no)	2003-09-26
CA2439241A1 (en)	2002-10-17
HUP0303724A3 (en)	2007-09-28
SK12422003A3 (sk)	2004-05-04
RU2296751C2 (ru)	2007-04-10

Publication	Publication Date	Title
EP1379504B1 (en)	2009-10-28	Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
AU2002302511A1 (en)	2003-04-10	Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
KR20010043032A (ko)	2001-05-25	1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체
US20030176693A1 (en)	2003-09-18	Diphenylalkylamine derivatives useful as opioid receptor agonists
CZ299824B6 (cs)	2008-12-03	Derivát piperidinu, zpusob jeho prípravy a použití a farmaceutický prostredek s jeho obsahem
US5814636A (en)	1998-09-29	Compounds with platelet aggregation inhibitor activity
EP0383579A1 (en)	1990-08-22	N-Phenyl-N-(4-piperidinyl)amides useful as analgesics
IL196059A (en)	2010-04-29	Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
AU2002353691A1 (en)	2003-07-24	Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
US4806547A (en)	1989-02-21	Isoquinoline derivatives, analgesic compounds thereof and method of treating pain
US20080249111A1 (en)	2008-10-09	Piperdine Derivatives as CCR5 Inhibitors
BRPI0512661B1 (pt)	2020-10-27	derivado de arilamidina ou um sal do mesmo, composto ou um sal do mesmo, e, composto antifúngico
EP1256575B1 (en)	2005-08-17	Phenoxyalkylamine derivatives useful as opioid delta receptor agonists
US3840529A (en)	1974-10-08	1-(1-(3-substituted-1-propenyl)-4-piperidyl)-2-oxobenzimidazolines
EP1760079A1 (en)	2007-03-07	Compounds as cor5 antagonists
CN101602708B (zh)	2012-11-21	芳烷醇哌啶衍生物及其在制备抗抑郁症药物中的应用
JP2004277319A (ja)	2004-10-07	１−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物